IL1B and disease of the tendon: Therapeutic strategies aimed at selectively eliminating senescent cells (senolytics) or modulating their secretory phenotype (senomorphics) may therefore hold promise for disrupting this vicious cycle in IL-1β-driven tendinopathy.